Brandon Biosciences Fund 1 IIF Partnership
(BBF1 IIF Partnership) |
|
St. Paul, Minnesota-based Osprey Medical Inc. (formerly V-Kardia Inc.) was founded in 2005 with a singular vision: to pioneer patent-pending catheter technologies that address unmet clinical needs in cardiovascular medicine. Backed by its seasoned management team and a $5 million Series A equity financing, Osprey Medical is now pursuing FDA approval for its first innovation—V-Focus CIN™ which addresses the problem of contrast induced nephropathy (CIN).
www.ospreymed.com |
|
Medical Research Commercialisation Fund (MRCF) |
To date, investment has been approved for projects only, the details of which will not be listed on this website. |
|
Australian Biomedical Funds 1, 2 & 3
(ABF1, ABF2, ABF3) |
|
Nanosonics Limited is a publicly listed company on the Australian Securities Exchange (ASX:NAN). The Company is developing a portfolio of decontamination products designed to reduce the spread of infection. Nanosonics owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.
www.nanosonics.com.au |
|
Stem Cell Sciences plc (AIM:STEM, ASX:STC) in a leading provider of cells and cell culture media to the burgeoning stem cell research market. The successful application of stem cells in both research and clinical applications is the reproducible supply of pure, fully characterised stem cells and stem cell-derived specialised cells such as nerves and muscle. By providing these products, to the life sciences industry and academia for use in basic research and drug discovery.
www.stemcellsciences.com |
|
Sunshine Heart (ASX:SHC) is a global medical technology company committed to the commercialisation of C-PulseTM, an implantable, non-blood contacting, heart assist therapy for the treatment of people with heart failure.
www.sunshineheart.com |
|
back to top
|
|
|
